OncologyImmunology & inflammationHematology ADC

Naratuximab emtansine dose and plasma exposure

Reference paper ↗

A reduced dose–exposure model for the CD37-directed ADC naratuximab emtansine, representing plasma decline and cumulative exposure across dose levels.

Therapeutic
Naratuximab emtansine, Naratuximab / K7153A
Modality
Antibody–drug conjugate (ADC)
Target
CD37
Disease
Relapsed or refractory B-cell non-Hodgkin lymphoma
Model type
ADC

Complete model workspace

Checking workspace access…

Parameters
9
States
3
Equations
3
Derived outputs
17

Explore this model

Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.

0.1 mg/kg exponential

How does dose level change naratuximab emtansine plasma concentration and cumulative exposure? Explore this biological starting configuration through Plasma naratuximab emtansine, Cumulative ADC exposure, Peak ADC concentration, Extrapolated total exposure.

Starting result

This result reflects the starting settings. Run your changes to update it.

Result preview could not load

The generated result could not be loaded. The inputs remain available below.

Starting configuration

Time: 0–504 hour; step 2

InputDefaultAvailable range
Selected dose0.1 mg/kg0.05–0.15 mg/kg
Selected half-life4.9 h2.45–7.35 h
Calibrated clearance linear6.94e-4 L/h/kg3.47e-4–0.001041 L/h/kg
Calibrated clearance tmdd0.01528 L/h/kg0.007642–0.02293 L/h/kg
Calibrated EC500.08187 mg/kg0.04093–0.1228 mg/kg

Expected readouts

Plasma naratuximab emtansine (ug/mL) · Exposure (AUC) (h*ug/mL) · Peak ADC concentration · Extrapolated total exposure

Adjustable model parameters

This public explorer exposes 5 curated parameters. Sign in to edit all 9 declared model parameters.

More key parameters (1)

How the model represents the biology

A reduced dose–exposure model for the CD37-directed ADC naratuximab emtansine, representing plasma decline and cumulative exposure across dose levels.

How does the selected empirical decay branch determine IMGN529 plasma exposure?A selected dose cohort initializes plasma IMGN529 concentration. A scenario chooses either a paper half-life-derived elimination constant or an exploratory elimination constant calibrated as Cmax divided by AUC infinity. The selected first-order rate removes plasma antibody-drug conjugate while concentration accumulates into an exposure integral.BIOLOGY OVERVIEWHow does the selected empirical decay branch determine IMGN529 plasma exposure?Selected dose cohortInitial plasma concentrationPlasma IMGN529Initialized concentrationstateDecay branch selectorHalf-life orCmax/AUC-calibrated kSingle-exponentiallossSelected first-ordereliminationCumulative exposurePlasma concentration integralPRIMARY READOUTSPlasma IMGN529Plasma IMGN529Cumulative AUCCumulative AUCSelected elimination rateSelected elimination rateExploratory calibrated Cmax and AUC∞Exploratory calibrated Cma…

Solid arrows show modeled movement or change; two-headed arrows show reversible exchange; dashed arrows show modulation without material transfer.

Model scope: CD37 binding or occupancy, ADC internalization, payload release, B-cell depletion, tumor response, toxicity, and multicompartment PK are not represented. Dose cohorts initialize a one-compartment empirical decay state.

Modeled relationships (4)
  • Selected dose cohort → Plasma IMGN529: initializes concentration (flow)
  • Decay branch selector → Single-exponential loss: selects kel branch (modulation)
  • Plasma IMGN529 → Single-exponential loss: first-order decay (loss)
  • Plasma IMGN529 → Cumulative exposure: integrates concentration (production)

Modeled relationships: Selected dose cohort to Plasma IMGN529: initializes concentration (flow); Decay branch selector to Single-exponential loss: selects kel branch (modulation); Plasma IMGN529 to Single-exponential loss: first-order decay (loss); Plasma IMGN529 to Cumulative exposure: integrates concentration (production).

Primary readouts: Plasma IMGN529; Cumulative AUC; Selected elimination rate; Exploratory calibrated Cmax and AUC∞.

Found a scientific issue? Email helpdesk@unibiointelligence.com with model ID stathis_2018_imgn529_cd37_adc_phase1_nca.

Research use only — not for patient-specific prediction or dosing advice.

Ubi Biologics